Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum.
Article in The Pediatric infectious disease journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors.
Flor M MunozFrom the Departments of Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.ORCID 0000-0002-0457-7689
Richard BeigiDepartment of Obstetrics, Gynecology and Reproductive Sciences, Magee-Women's Hospital, Pittsburgh, PA.ORCID 0000-0003-3932-8217
Christine M PosavadVaccine and Infectious Disease Division, Department of Laboratory Medicine and Pathology.ORCID 0000-0003-3894-2784
Clifton KellyStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0003-0794-3901
Martina L BadellDivision of Maternal Fetal Medicine, Department of Gynecology and Obstetrics, Emory University Hospital Midtown Perinatal Center, Atlanta, GA.ORCID 0000-0003-1793-9666
Katherine BungeDepartment of Obstetrics, Gynecology and Reproductive Sciences, Magee-Women's Hospital, Pittsburgh, PA.ORCID 0000-0003-3940-8102
Mark J MulliganDepartment of Medicine, NYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, NYU Grossman School of Medicine, New York, NY.ORCID 0000-0001-7262-9746
Lalitha ParameswaranDepartment of Medicine, NYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, NYU Grossman School of Medicine, New York, NY.ORCID 0000-0002-5566-9495
Barbra A RichardsonVaccine and Infectious Disease and Public Health Sciences Divisions, Departments of Biostatistics and Global Health, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.ORCID 0000-0001-9564-1828
Courtney Olsen-ChenDepartment of Obstetrics and Gynecology, University of Rochester, Rochester, NY.ORCID 0000-0003-3767-0502
Richard M NovakDivision of Infectious Diseases, University of Illinois, Chicago, IL.ORCID 0000-0002-3199-8040
Rebecca C BradyDivision of Infectious Diseases, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH.ORCID 0000-0002-1064-2213
Emily DeFrancoDivision of Infectious Diseases, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH.ORCID 0000-0002-0164-5703
Jeffrey S GerberDivision of Infectious Diseases, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0002-3076-3186
Mallory ShriverCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD.ORCID 0009-0006-6536-3218
Mehul S SutharDepartment of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory School of Medicine, Emory University, Atlanta, GA.ORCID 0000-0002-2686-8380
Rhea ColerSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA.ORCID 0000-0001-6974-5666
Bryan J BerubeSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA.ORCID 0000-0002-3287-0583
So Hee KimStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0003-4558-3943
Jeanna M PiperNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD.ORCID 0000-0001-7862-7899
Marcela PasettiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD.ORCID 0000-0003-0894-4009
Kathleen M NeuzilCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD.ORCID 0000-0001-9480-2714
Cristina V CardemilNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD.ORCID 0000-0002-5898-6154
DMID Study Group
Funding
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2M
VTEU SupplementUM1AI148689 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Karen L. Kotloff · 2020 to 2026
$52.7M
Vanderbilt Vaccine and Treatment Evaluation Unit - KidCOVEUM1AI148452 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Clarence Buddy Creech · 2020 to 2026
$51.3M
Vaccine and Treatment Evaluation Units - DMID 21-0012UM1AI148576 · NIAID · EMORY UNIVERSITY · PI Nadine Georges Rouphael, Carlos del Rio · 2020 to 2026
$41.7M
Vaccine and Treatment Evaluation Unit at Saint Louis University - DMID 20-0034UM1AI148685 · NIAID · SAINT LOUIS UNIVERSITY · PI Daniel F. Hoft · 2020 to 2026
$34.6M
Vaccine and Treatment Evaluation Units (VTEU)-DMID 21-0004UM1AI148575 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI HANA M EL SAHLY · 2020 to 2026
$29.4M
Kaiser Washington VTEU supplement 20-0003UM1AI148373 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI LISA A JACKSON · 2020 to 2026
$24.4M
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012UM1AI148574 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Angelica Cifuentes Kottkamp, Anoma Nellore · 2020 to 2026
$23.9M
University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)-mRNA-1273-P204 Moderna Pediatric StudyUM1AI148450 · NIAID · UNIVERSITY OF ROCHESTER · PI Angela Ramona Branche, Ann R Falsey · 2020 to 2026
$20.6M
Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) - Moderna Pediatric StudyUM1AI148372 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI Robert Wilson Frenck · 2020 to 2026
$20.5M
Neuro HPA Project 1U54AG062334 · NIA · EMORY UNIVERSITY · PI Ighovwerha Ofotokun · 2018 to 2026
$12.2M
Emory R38 Research Training ProgramR38AI174306 · NIAID · EMORY UNIVERSITY · PI Nadine Georges Rouphael · 2023 to 2026
backgroundFollowing maternal COVID-19 vaccination, the persistence of antibodies in sera and breast milk for mothers and infants is not well characterized. We sought to describe the persistence of antibodies through 2 months after delivery in maternal and infant serum and breast milk following maternal COVID-19 mRNA vaccination and to examine differences by receipt of booster dose during pregnancy or postpartum.
methodsThis is a prospective cohort study with enrollment from July 2021 to January 2022 at 9 US academic sites. Pregnant or postpartum participants and their infants were enrolled after COVID-19 mRNA monovalent vaccination during pregnancy (primary 2-dose series) with booster (third dose) vaccination during pregnancy or within 2 months post-partum. SARS-CoV-2-binding and functional antibody responses at delivery and 2 months after delivery in mothers and infants were measured by spike and receptor-binding domain immunoglobulin (Ig) G, pseudovirus and live neutralizing antibody (nAb) titers to ancestral and Omicron BA.1 and BA.5 strains. Breast milk spike and receptor-binding domain IgG and IgA titers were also measured.
resultsA total of 237 maternal/infant dyads were included (110 primary series during pregnancy, 99 pregnancy booster and 28 postpartum booster). A pregnancy booster resulted in 2.2-4.7-fold higher IgG and nAb at delivery and 2 months for both mothers and infants compared to the primary series alone (P < 0.001 for all comparisons). While infant IgG and nAb titers decreased by 2 months of age, the proportion of infants with detectable nAb at 2 months was greater in infants of mothers boosted during pregnancy compared with primary series for all variants (D614G: 99% vs. 56%; BA.1: 56% vs. 4% and BA.5: 57% vs. 9%; P < 0.001 for all comparisons). Breast milk spike IgA and IgG were present in 64%-100% and 100% of participants, respectively, and those boosted during pregnancy or postpartum had 3.1-4.6-fold higher levels of breast milk antibodies at 2 months compared to primary series during pregnancy (P < 0.001).
conclusionsmRNA COVID-19 monovalent booster vaccination during pregnancy results in significantly higher maternal and infant serum-binding IgG and nAb titers compared to a primary 2-dose series, including against Omicron variants, through 2 months of age. Breast milk antibodies following maternal vaccination during pregnancy or postpartum may provide additional protection during early infancy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum. · full record | OpenQuestion